HER2-low is a newer way of describing a HER2 test result: the cancer cells have some HER2 protein on their surface, but not enough for the cancer to be called HER2-positive. It sits between HER2-negative, where no HER2 is found, and HER2-positive, where there is a great deal of it. If the words “HER2-low” have appeared on your pathology report or in something you have read, this article explains what the term means in general terms.
Key Takeaways
- HER2 is a protein that sits on the surface of breast cells. Laboratory tests measure how much of it a cancer has.
- “HER2-low” describes a result with a low amount of HER2 — more than none, but below the level called HER2-positive.
- It is a description of a test result, not a separate type of breast cancer, and it does not replace the other words on your report.
- The category is newer: older reports usually sorted these same results under “HER2-negative.”
- What the result means for your treatment is individual. Your care team interprets it alongside your hormone receptor results, grade, and stage.
- General background is published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov).
What HER2 Is
HER2 is a protein found on the surface of normal breast cells, where it plays a part in how cells grow and divide. In some breast cancers, the cancer cells make far too much of this protein, and that extra HER2 can drive the cancer to grow. In others, the amount is ordinary or low. Because the level can change how a cancer behaves and which treatments can act on it, HER2 testing is a standard part of examining a breast cancer biopsy.
The result is one of several standard descriptions on a pathology report, alongside the estrogen and progesterone receptor results, the grade, and later the stage. Our pillar guide, Types of Breast Cancer Compared, shows how these descriptions fit together. A single cancer carries several of them at once, and each one tells the care team something different.
Where “HER2-Low” Fits
For many years, HER2 results were sorted into two groups: positive, meaning a high level that HER2-directed treatments could target, and negative, meaning everything below that. “Negative” was always a wide group — it included cancers with no HER2 at all and cancers with a small amount. The term “HER2-low” simply names the lower-but-not-zero part of that old negative group.
| Description | What it means, in general terms |
|---|---|
| HER2-negative (no HER2 found) | The tests show no HER2 protein on the cancer cells |
| HER2-low | The tests show a low amount of HER2 — present, but below the level called positive |
| HER2-positive | The tests show a high amount of HER2, or extra copies of the HER2 gene |
Nothing about the cancer itself changed when this word appeared — it is a finer label for results laboratories were already producing. Our comparison article, HER2-Positive vs HER2-Negative Breast Cancer, explains the older two-way split in more detail, and HER2-low is best understood as a subdivision within the negative side of it.
You may meet the term in several places: in the pathology report itself, in a clinic letter summarising your results, on a patient portal, or in reliable general reading about breast cancer. It can look alarming to meet an unfamiliar label with no explanation attached, especially if the words on your portal do not match the words your doctor used in the room. That mismatch is usually just the newer vocabulary catching up with the older one, not a disagreement about your result — but it is always fair to ask which description your own team uses for your cancer, and to have them point to the exact lines on your report that it comes from.
How the Result Is Found
HER2 is measured on the biopsy tissue in the laboratory, usually in two steps described in general terms on most reports. The first test, often shortened to IHC, stains the tissue to show how much HER2 protein sits on the cells, and the result is reported as a score. Low and middle scores can be hard to place, so a second test, often shortened to ISH, may be used to check whether the cells carry extra copies of the HER2 gene itself.
Read together, in general terms: a high protein score, or extra gene copies, places a cancer in the HER2-positive group. No protein found places it in the HER2-negative group. A low protein score without extra gene copies is the pattern now described as HER2-low. The exact wording on reports varies between laboratories, so treat this as the general shape of the system rather than a reading of your own result — your care team can walk you through the lines on your report and what they mean in your case.
It is also worth knowing that HER2 results can occasionally differ between a biopsy and later tissue, or between samples. If your paperwork seems to use different words in different places, that is a good question to raise rather than a puzzle to solve alone.
What It Can Mean for Treatment Planning
The reason the HER2-low label has drawn attention is treatment. The long-standing HER2-directed treatments were developed for cancers with high HER2 levels. More recently, researchers have studied whether some HER2-directed approaches can also help certain cancers with low levels, and this is an area where practice continues to develop. This article names no drugs and makes no promises: whether any of this applies to you depends on your full report, your situation, and the judgement of your own doctor and care team.
HER2-low also overlaps with the other descriptions in ways that can confuse. A HER2-low cancer may be hormone receptor-positive or hormone receptor-negative. If the hormone receptors are also absent, older wording may have grouped the same cancer with the triple-negative cancers — which is why our article Triple-Negative vs HER2-Positive Breast Cancer is a useful companion read. Individual cases differ a great deal, and two reports that both say “HER2-low” can describe quite different situations and plans.
Questions to Ask Your Doctor
- What exactly does my pathology report say about HER2, and would my team describe the result as HER2-low?
- What were my estrogen and progesterone receptor results, and how do they fit with the HER2 result?
- Was the second HER2 test (ISH) done, and what did it show?
- Does the HER2 level change anything about the treatment being planned for me, in general terms?
- If my biopsy and surgery reports describe HER2 differently, which result is my plan based on?
- Where can I read reliable general information about how HER2 results are used?
Frequently Asked Questions
Is HER2-low a separate type of breast cancer?
No. It is a description of one test result — a low level of the HER2 protein — not a type of its own. Your cancer is still described by where it began, its grade and stage, and its hormone receptor results as well. The words work together rather than replacing each other.
Why does my older report not mention HER2-low?
Because the term is newer. For many years, results with a low level of HER2 were simply grouped under “HER2-negative.” The tests were the same; the labelling has become more detailed. If you are being treated now, your current team can tell you how they would describe your result today.
Does HER2-low mean my cancer is less serious?
There is no single answer from this one result. How a cancer behaves depends on the whole picture — stage, grade, hormone receptor results, and how it responds to treatment — rather than on the HER2 level alone. Your care team can explain how the pieces fit together in your case.
Is HER2-low the same as triple-negative?
Not exactly. Triple-negative describes three absent results: estrogen receptors, progesterone receptors, and high HER2. A HER2-low cancer with absent hormone receptors may previously have been counted in that group, while a HER2-low cancer with present hormone receptors was not. The vocabularies overlap, which is why asking your team to explain your exact combination is worthwhile.
Where can I read more?
Our pillar guide compares the main types side by side, and general information about HER2 testing is published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov). Your own report, explained by your own team, is the source that matters most.
Related Articles
- Types of Breast Cancer Compared: A Complete Guide
- HER2-Positive vs HER2-Negative Breast Cancer
- Triple-Negative vs HER2-Positive Breast Cancer
- Basal-Like Breast Cancer Explained in Plain English
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.